Médecins en Oncologie à Canton, Chine — Page 2

Jian-Hua Fu is a specialist at Sun Yat-sen University Cancer Center, where he is Professor of thoracic cancers and Director of the Guangdong Esophageal Cancer Institute. He specializes in minimally invasive esophagectomy and minimally invasive thoracic surgery for esophageal cancer. His advanced training includes a 2002 specialization at Prince of Wales Hospital (CUHK) and lung transplantation study at Toronto General Hospital in 2004.

Huang Jinhua is a specialist at Sun Yat-sen University Cancer Center, working in Interventional Radiology with over 20 years of experience in minimally invasive cancer therapy. He performs interventional treatments such as transarterial chemoembolization and radiofrequency ablation for solid tumors. His long training path includes a Fellow period in Radiology and Interventional Radiology at the same cancer center (1988–1995).

Desheng Weng is a specialist at Sun Yat-sen University Cancer Center, where he is an Associate Professor and Deputy Director in the Biotherapy Center / Melanoma and Sarcoma Medical Oncology. He combines cancer genetics research with immunotherapy-focused oncology care. His research includes studying tumor suppressor genes such as ING2, TESTIN, BATF2, LZAP, and BIN1 and their links to clinical features in hepatocellular carcinoma and gastric cancer.

Chen Likun is a specialist at Sun Yat-sen University Cancer Center, working in Medical Oncology as an Associate Professor. She focuses on lung cancer and esophageal cancer and participates in oncology leadership through CSCO and Guangdong anticancer committees. A concrete recognition is her 2008 “Ceclor Best Chinese Doctors” award.

Binkui Li is a specialist at Sun Yat-sen University Cancer Center, serving as Professor, PhD supervisor, and Director of Liver Surgery. He treats liver cancers with a multidisciplinary program that combines surgery, vascular interventional therapy, targeted therapy, and immunotherapy. A key differentiator is his conversion-therapy approach for advanced liver cancer to make surgery possible when it initially isn’t.